Binnopharm Group and the Chinese biopharmaceutical company Mabwell have signed an agreement on the localization in Russia and the EAEU countries of another drug based on monoclonal antibodies, dupilumab– for the treatment of atopic dermatitis and bronchial asthma.
The agreement builds on a successful partnership between the companies that began in 2022, when Binnopharm Group acquired exclusive rights to manufacture, register and sell certain drugs developed by Mabwell. Production facilities for their full-cycle production, including the production of the substance, have been built and put into operation at the company's site in Zelenograd. It is planned to be the first to release drugs for the treatment of rheumatoid arthritis and osteoporosis on the Russian market. Registration certificates and the launch of drugs on the market are planned for early 2026.
Rustem Muratov, CEO of Binnopharm Group:
"The successful implementation of ongoing projects with Mabwell creates a solid foundation for considering new joint initiatives. The creation of a full–cycle production facility in Zelenograd – from growing cell lines to purification, formulation and release of the finished dosage form for the first drugs - has shown our ability to implement complex biopharmaceutical projects in a short time. We are starting work on localization of the next promising product, dupilumab, and we are confident that our accumulated experience and the created infrastructure will allow us to implement this project just as effectively."
According to AlphaRM, the annual sales volume of medicines with the active substance dupilumab in the tender segment exceeds 5 billion rubles, which allows it to enter the TOP 50 drugs in terms of sales in rubles. At the same time, the growth in 9 months of 2025 in monetary terms amounted to 53% compared to the same period last year.
Please note that this press release is based on materials provided by the company. AK&M Information Agency shall not be held liable for its contents, nor for the legal and other consequences of its publication.
